Five recently published randomized trials of endovascular therapy versus medical management, including intravenous thrombolysis, demonstrated strong positive data in support of intra-arterial thrombectomy procedures. The American Heart Association/American Stroke Association released a focused update of the 2013 guidelines on the early management of acute ischemic strokes to specifically incorporate the findings of the 5 "positive" trials. In this review, we examine the key results of those trials and the principal changes in the updated guidelines. We discuss the ongoing and future changes in stroke systems of care, with an emphasis on the role of pre-hospital stroke triage, interhospital transfer, and the 2 main levels of stroke center certification (primary and comprehensive). 
typically includes the intracranial internal carotid artery, proximal middle cerebral artery, and the basilar artery, accounts for approximately 39% to 46% of all ischemic strokes and is associated with poor prognosis and neurological outcome (2) (3) (4) . The most common etiology of intracranial LVO is cardioembolism, which is reported in 59% of all strokes from LVO, followed by large-artery atherosclerosis (22%) (5) . However, in certain populations of patients, such as Asian subjects, large-artery atherosclerosis is more common, making it the number 1 cause of acute stroke from LVO (6) . Other causes of LVO, such as a dissection and hypercoagulable and inflammatory states, are less common and tend to occur in a younger population of patients (7) (8) (9) .
Parallel to the widespread use of IV rtPA, over the last 2 decades, various intra-arterial As a result, efforts have now shifted toward the changes that existing stroke care systems need to implement, as the status of endovascular stroke therapy in certain stroke patient populations has transformed from "experimental and unproven" to "evidence-based and recommended." These efforts are currently endorsed and supported by major medical organizations and societies, such as the American Heart Association (AHA)/American Stroke Association (ASA) and the Society of NeuroInterventional Surgery (SNIS) (11, 12) . In the present review, we refer to the key results of those 5 trials, discuss the updated guidelines of endovascular stroke therapy, and focus on the current state and prospective changes in stroke care systems. Using Embolectomy] [24] ), which had been published 2 years before. Much has been written about the reasons why those 3 earlier trials "failed" to show the benefit of endovascular therapy (25) (26) (27) . It is important to recognize that it is the availability of both (28) . Successful recanalization is defined as TICI or modified TICI 2b/3. Rates of successful recanalization are much higher with stent retrievers than with earlygeneration thrombectomy devices (29, 30) . In the recent trials, these rates varied from 59% in MR CLEAN to 86% in SWIFT PRIME (the lowest and highest TICI 2b/3 achieved among the 5 trials, respectively). The SNIS worded their guidelines on the management of acute stroke differently, recommending "endovascular embolectomy," rather than a specific type of a thrombectomy device (12) .
RECENT ENDOVASCULAR STROKE TRIALS AND UPDATED GUIDELINES
The strongest recommendation made by the AHA/ ASA for thrombectomy was given for anterior circulation strokes when intervention could be initiated within the first 6 h of stroke onset after the administration of IV rtPA; this recommendation is a reflection of the most common population of patients Treatment for Acute Ischemic Stroke) (13) European-based study (Netherlands), which enrolled 500 patients Intra-arterial treatment initiated within the first 6 h (97% of which were with stent retrievers with or without preceding use of IV rtPA) was compared with standard medical therapy alone (IV rtPA in 91% of cases) Good neurological outcome (functional independence) at 3 months was achieved in 33% with endovascular treatment versus 19% of medical therapy (control group) patients After early release of trial results, the other similar ongoing trials (ESCAPE, SWIFT PRIME, EXTEND IA, and REVASCAT) were halted for ethical concerns because of loss of equipoise preventing further enrollment in those trials 
CURRENT STATUS OF ENDOVASCULAR STROKE THERAPY
Presently, we lack systematic data on patient access to emergent endovascular stroke therapy nationwide. In addition, active involvement by local government support increases access to stroke thrombolysis, 
LEVELS OF STROKE CENTER CERTIFICATION
Presently, several pathways can be followed to 
